Ready to invest in stocks?
Discover the best brokers to get started.

BeOne Medicines

ISIN US07725L1026

 | 

WKN A1437N

Market cap (in EUR)
28,171 m
Country
Switzerland
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Switzerland

Financials

Key metrics

Market capitalisation, EUR 28,171 m
EPS, EUR 3.87
P/B ratio 6.2
P/E ratio 59.0
Dividend yield 0.00%

Income statement (2025)

Revenue, EUR 4,749 m
Net income, EUR 255 m
Profit margin 5.37%

What ETF is BeOne Medicines in?

There are 7 ETFs which contain BeOne Medicines. All of these ETFs are listed in the table below. The ETF with the largest weighting of BeOne Medicines is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
ETF Weight Investment focus Fund size (in m EUR)
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C 1.76%
Equity
World
Health Care
Social/Environmental
Innovation
8
iShares Emerging Markets Equity Enhanced Active UCITS ETF USD (Acc) 0.01%
Equity
Emerging Markets
Social/Environmental
Multi-Asset Strategy
1,188
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.76%
Equity
United States
Health Care
Biotech
46
iShares Nasdaq US Biotechnology UCITS ETF 0.76%
Equity
United States
Health Care
Biotech
736
First Trust NYSE Arca Biotechnology UCITS ETF Acc 3.11%
Equity
United States
Health Care
Biotech
10
iShares Emerging Markets Equity Enhanced Active UCITS ETF (Dist) 0.01%
Equity
Emerging Markets
Social/Environmental
Multi-Asset Strategy
59
L&G Pharma Breakthrough UCITS ETF 2.59%
Equity
World
Health Care
Innovation
16

Savings plan offers

Here you can find information about the savings plan availability for the stock. You can use the table to compare savings plan offers for the selected savings rate.
 
Broker Rating Execution fee Account fee
0.00 €
0.00 €
View offer*
Source: justETF Research; as of 6/2026. The offers are sorted in the following way: 1. Rating 2. Execution fee 3. Number of stock savings plans. The number of stock savings plans is rounded. In addition to the fees charged by online brokers, additional costs may apply. The stated fees are thus exclusive of standard market spreads, commissions, product costs and third-party fees. Please note: No guarantee can be given for the completeness, correctness and accuracy of the content listed. The information on the online brokers' homepages is decisive. Investments in securities involve risks.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable GmbH. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.